Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan L Epstein

Showing results (91-100 of 98) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 98 results.
Molecular Cancer Therapeutics|October 5, 2021
NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor MicroenvironmentTiange Dong, Priyal Dave, EunJeong Yoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancerShaoliang Chen, Like Yu, Changying Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Leukemia|December 15, 2019
Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tractGuangzhen Hu, Jessica L Phillips, Surendra Dasari, et al.
Nature Communications|February 14, 2019
Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetesLauriane Galle-Treger, Ishwarya Sankaranarayanan, Benjamin P Hurrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2017
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutationsJing Chen, Yong Zhang, Michael N Petrus, et al.
Haematologica|May 17, 2020
Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphomaNaoki Oishi, Tanya Hundal, Jessica L Phillips, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Pageof 10

Showing results (91-100 of 98) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
Molecular Cancer Therapeutics|October 5, 2021
NAP1051, a Lipoxin A4 Biomimetic Analogue, Demonstrates Antitumor Activity Against the Tumor MicroenvironmentTiange Dong, Priyal Dave, EunJeong Yoo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2005
Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancerShaoliang Chen, Like Yu, Changying Jiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2012
An in vivo immunotherapy screen of costimulatory molecules identifies Fc-OX40L as a potent reagent for the treatment of established murine gliomasKatherine A Murphy, Melissa G Lechner, Flavia E Popescu, et al.
Leukemia|December 15, 2019
Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tractGuangzhen Hu, Jessica L Phillips, Surendra Dasari, et al.
Nature Communications|February 14, 2019
Costimulation of type-2 innate lymphoid cells by GITR promotes effector function and ameliorates type 2 diabetesLauriane Galle-Treger, Ishwarya Sankaranarayanan, Benjamin P Hurrell, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 31, 2017
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutationsJing Chen, Yong Zhang, Michael N Petrus, et al.
Haematologica|May 17, 2020
Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphomaNaoki Oishi, Tanya Hundal, Jessica L Phillips, et al.
Nature Communications|May 24, 2018
Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical modelsSamuel Y Ng, Noriaki Yoshida, Amanda L Christie, et al.
Pageof 10